JP2021517128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021517128A5 JP2021517128A5 JP2020546876A JP2020546876A JP2021517128A5 JP 2021517128 A5 JP2021517128 A5 JP 2021517128A5 JP 2020546876 A JP2020546876 A JP 2020546876A JP 2020546876 A JP2020546876 A JP 2020546876A JP 2021517128 A5 JP2021517128 A5 JP 2021517128A5
- Authority
- JP
- Japan
- Prior art keywords
- levodopa
- carbidopa
- secant
- top layer
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 34
- 229960004502 levodopa Drugs 0.000 claims 34
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 33
- 229960004205 carbidopa Drugs 0.000 claims 17
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 9
- 229940052036 carbidopa / levodopa Drugs 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 229940015929 carbidopa 12.5 mg Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004044 response Effects 0.000 claims 4
- 241000255925 Diptera Species 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229940067290 levodopa 50 mg Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 238000011272 standard treatment Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110134A JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650012P | 2018-03-29 | 2018-03-29 | |
| US62/650,012 | 2018-03-29 | ||
| PCT/US2019/024464 WO2019191353A1 (en) | 2018-03-29 | 2019-03-28 | Levodopa fractionated dose composition and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110134A Division JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517128A JP2021517128A (ja) | 2021-07-15 |
| JP2021517128A5 true JP2021517128A5 (enExample) | 2021-08-26 |
Family
ID=68060752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546876A Pending JP2021517128A (ja) | 2018-03-29 | 2019-03-28 | レボドパ分割用量組成物および使用 |
| JP2022110134A Pending JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110134A Pending JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11033521B2 (enExample) |
| EP (1) | EP3773532A4 (enExample) |
| JP (2) | JP2021517128A (enExample) |
| CN (1) | CN111954523A (enExample) |
| BR (1) | BR112020017422A2 (enExample) |
| CA (1) | CA3095341A1 (enExample) |
| WO (1) | WO2019191353A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095341A1 (en) * | 2018-03-29 | 2019-10-03 | Avion Pharmaceuticals, Llc | Levodopa fractionated dose composition and use |
| US20220071909A1 (en) * | 2020-08-26 | 2022-03-10 | Rubicon Research Private Limited | Modified release formulations of levodopa |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061494A (en) * | 1990-06-14 | 1991-10-29 | The Upjohn Comany | Tri-scored drug tablet |
| US8158148B2 (en) * | 2004-05-21 | 2012-04-17 | Accu-Break Technologies, Inc. | Pharmaceutical tablets comprising two or more unitary segments |
| CN1960713A (zh) * | 2004-05-21 | 2007-05-09 | 阿库-伯雷克技术公司 | 含有两个或多个单元片段的药片 |
| US7838031B2 (en) | 2004-05-21 | 2010-11-23 | Lawrence Solomon | Method of administering a partial dose using a segmented pharmaceutical tablet |
| US8506999B2 (en) | 2005-05-23 | 2013-08-13 | Accu-Break Technologies, Inc. | Pharmaceutical tablets comprising a plurality of segments |
| US20070275060A1 (en) * | 2005-08-05 | 2007-11-29 | Osmotica Costa Rica Sociedad Anonima | Extended release solid pharmaceutical composition containing carbidopa and levodopa |
| WO2007058660A1 (en) | 2005-11-18 | 2007-05-24 | Accu-Break Technologies, Inc. | Segmented pharmaceutical dosage forms |
| CN101636145B (zh) * | 2006-05-31 | 2014-04-23 | 雅培产品有限公司 | 长期24小时经肠给予左旋多巴/卡比多巴 |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| US9289392B2 (en) * | 2008-08-22 | 2016-03-22 | Wockhardt Ltd. | Extended release pharmaceutical composition of entacapone or salts thereof |
| EP3777839A1 (en) * | 2009-05-19 | 2021-02-17 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| US20160022573A1 (en) * | 2013-03-13 | 2016-01-28 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| CA2907886A1 (en) * | 2013-03-28 | 2014-10-02 | Omniactive Health Technologies Limited | Neuroprotective effect of carotenoids in brain |
| JP2018500300A (ja) * | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| WO2018034626A1 (en) * | 2016-08-18 | 2018-02-22 | İlko İlaç Sanayi Ve Ticaret Anonim Şirketi | Antiparkinson tablet formulation with improved dissolution profile |
| CA3095341A1 (en) * | 2018-03-29 | 2019-10-03 | Avion Pharmaceuticals, Llc | Levodopa fractionated dose composition and use |
-
2019
- 2019-03-28 CA CA3095341A patent/CA3095341A1/en active Pending
- 2019-03-28 JP JP2020546876A patent/JP2021517128A/ja active Pending
- 2019-03-28 WO PCT/US2019/024464 patent/WO2019191353A1/en not_active Ceased
- 2019-03-28 BR BR112020017422-0A patent/BR112020017422A2/pt unknown
- 2019-03-28 CN CN201980023074.8A patent/CN111954523A/zh active Pending
- 2019-03-28 EP EP19775769.3A patent/EP3773532A4/en not_active Withdrawn
- 2019-12-18 US US16/719,203 patent/US11033521B2/en active Active
-
2021
- 2021-03-31 US US17/219,253 patent/US11439613B2/en active Active
-
2022
- 2022-07-08 JP JP2022110134A patent/JP2022133449A/ja active Pending
- 2022-08-26 US US17/896,808 patent/US11819485B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102795284B1 (ko) | 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법 | |
| US11458110B2 (en) | Treatment of Fragile X Syndrome with cannabidiol | |
| Schapira et al. | Study on the effects of tablet colour in the treatment of anxiety states | |
| ES2214729T3 (es) | Acido 9-cis-retinoico para enfermedades inmunes inducidas por celulas. | |
| Rigante et al. | The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| AU2310200A (en) | Pharmaceutical compositions | |
| HUE035105T2 (en) | A composition comprising nicotine and opipramole and its use | |
| US11826321B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| JP2021517128A5 (enExample) | ||
| EP4661867A1 (en) | Compositions comprising n,n-dimethyltryptamine, optionally in combination with n-acylethanolamines and uses thereof | |
| AU2023231494A1 (en) | Compositions comprising meai and n-acylethanolamines and uses thereof | |
| ES2677474T3 (es) | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos | |
| JP2011121976A (ja) | 線維筋痛症に伴う口腔乾燥症を改善するための線維筋痛症に伴う口腔乾燥症改善用医薬組成物 | |
| CN120659608A (zh) | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 | |
| Bourde et al. | Controlled Clinical Trial Of An Antiaggregating Agent, Ti-Clopidine, In Vascular Ulcers Of The Leg | |
| FR2647784A1 (fr) | Association de vitamine a a dose physiologique et de differents principes actifs ayant une activite therapeutique | |
| CN104906501A (zh) | 治疗银屑病的中药组分组合物 | |
| US11826326B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| JPWO2022064387A5 (enExample) | ||
| JP2018177773A (ja) | 医薬 | |
| JP2007513095A5 (enExample) | ||
| US11219659B2 (en) | Methods and compositions for treating schizophrenia and schizoaffective disorders | |
| US20210179623A1 (en) | New chemical compound containing active enantiometer s-(-) ketorolac tromethamine for the treatment of pain | |
| Arora et al. | COMPARATIVE EFFICACY OF TACROLIMUS 0.03% OINTMENT AND TRIAMCINOLONE ACETONIDE 0.1% OINTMENT IN TREATMENT OF ORAL LICHEN PLANUS. |